Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) and Vireo Growth (OTCMKTS:VREOD – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.
Profitability
This table compares Arcutis Biotherapeutics and Vireo Growth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arcutis Biotherapeutics | 6.15% | 15.05% | 6.51% |
| Vireo Growth | -23.37% | -19.76% | -7.15% |
Risk & Volatility
Arcutis Biotherapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Vireo Growth has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arcutis Biotherapeutics | $376.07 million | 8.17 | -$16.14 million | $0.21 | 116.43 |
| Vireo Growth | $268.77 million | 1.68 | -$68.11 million | ($3.30) | -3.02 |
Arcutis Biotherapeutics has higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for Arcutis Biotherapeutics and Vireo Growth, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arcutis Biotherapeutics | 0 | 3 | 6 | 0 | 2.67 |
| Vireo Growth | 1 | 0 | 0 | 0 | 1.00 |
Arcutis Biotherapeutics currently has a consensus price target of $35.57, suggesting a potential upside of 45.48%. Given Arcutis Biotherapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Vireo Growth.
Summary
Arcutis Biotherapeutics beats Vireo Growth on 11 of the 12 factors compared between the two stocks.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
About Vireo Growth
Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
